CALL US NOW 0207 939 0780
PLEASE DONATE

TREATMENT

Announcement from NHSE on Inhibitor Treatment

NHSE has announced that Emicizumab (marketed as Hemlibra) can be provided to Haemophilia A patients with current inhibitors under the Framework Agreement for the supply of products for the treatment of bleeding disorders as an in year service development. From 1st July it will be available for routine prophylaxis to Haemophilia

Read More

Take part in our inhibitor survey

We’re conducting a survey among people aged 16+ with a bleeding disorder who have an inhibitor and their family members. An inhibitor is a type of antibody that prevents factor replacement treatment from working. When an inhibitor develops, it binds to factor concentrates such as factor VIII or factor IX,

Read More

UK launches FibCLOT®▼ LFB’s human fibrinogen concentrate

LFB Biopharmaceuticals announced today the UK launch of FibCLOT, its human fibrinogen concentrate. This follows the granting of a UK Marketing Authorisation in April 2016, after a decentralised application to the Regulatory Authorities in Europe, and offers increased therapeutic choices for affected patients. FibCLOT® is indicated for the treatment and perioperative

Read More